Citron Research

About the Author Citron Research

Citron Research has been publishing columns for over 11 years, making it one of the longest-running online stock commentary websites. With over 150 reports, Citron has amassed a track record identifying fraud and terminal business models second to none among any published source. The goal of this website is and has always been to provide truthful information in an entertaining format to the investing public. Our goal has never been to engage in “gotcha” journalism. Readers are always encouraged to consider this and all information available regarding any potential investments, to seek professional assistance as necessary, and to draw their own conclusions.

Citron Research Cautious on AVX Corporation (AVXS); Sees at Least 43% Downside

Rarely in biotech do we see a situation where an investor can simply perform their own due diligence and be on the right …

Valeant Pharmaceuticals Intl Inc (VRX): Business Model is Broken, Stock is Too Dangerous to Own

Over the past two weeks, shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) took a steep decline over concerns of price gouging that was recently …

Ambarella Inc (AMBA): Examining The Bearish Thesis

It seems like yesterday that Wall Street was frothing at the mouth over 3D printing stocks. These high flyers were not valued based …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts